Literature DB >> 28221155

Super-mini PCNL (SMP): Material, indications, technique, advantages and results.

Zhijian Zhao1, Aierken Tuerxu2, Yongda Liu1, Wenqi Wu1, Abulizi Simayi3, Wen Zhong1, Wenzhong Chen1, Abudukahaer Batuer2, Guohua Zeng1.   

Abstract

OBJECTIVE: To introduce an emerging technique termed 'super-mini- percutaneous nephrolithotomy' (SMP) and describe its application in practice.
METHODS: We described the technique of SMP in the treatment of renal stones with emphasis on the material, indications, technique procedure, advantages, and results.
RESULTS: SMP refers to a 7 Ch. nephroscope placed through a 10-14 Ch. metal access sheath with functions of both irrigation and suction-evacuation, to achieve stone fragmentation via laser or pneumatic lithotripsy. We reported our experience of this technique in 342 cases including 231 adults and 111 children. The mean stone size was 2.3 ± 0.9 cm resulted in 54.3 ± 27.7 min of mean operative time in adults, as well as 39.4 ± 26.2 min for stone size of 1.4 ± 0.5cm in children. In parallel, the initial stone-free rate (SFR) was 89.2% and 90.0% followed with a 94.4% and 95.5% of final SFR at 3 months in adults and children, respectively. No transfusions were needed in all patients. Tubeless was achieved in 93.9% and 100%of patients in adults and children respectively. The mean hospital stay was 2.3 ± 0.8 d and 2.7 ± 1.5 d respectively.
CONCLUSIONS: SMP are suited for stones less than 2.5 cm in size. It is also suited for special situations such as pediatric moderate-sized stones, previously failed SWL or RIRS approaches. It has advantages of a shorter operative time and hospital stays, with a largely reduction use of drainage catheter after procedure. The indications of the SMP may also compete with those of SWL and RIRS.

Entities:  

Mesh:

Year:  2017        PMID: 28221155

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  8 in total

1.  Comparison of super-mini versus mini percutaneous nephrolithotomy for the treatment of upper urinary tract stones in children: a single centre experience.

Authors:  Abulizi Simayi; Peng Lei; Talaiti Tayier; Aihemaiti Aimaier; Zhang Xiao'an; Yalikun Alimu
Journal:  Pediatr Surg Int       Date:  2021-05-21       Impact factor: 1.827

Review 2.  Miniaturisation of PCNL.

Authors:  Sven Lahme
Journal:  Urolithiasis       Date:  2017-12-14       Impact factor: 3.436

Review 3.  Research progress of percutaneous nephrolithotomy.

Authors:  Chao Wei; Yucong Zhang; Gaurab Pokhrel; Xiaming Liu; Jiahua Gan; Xiao Yu; Zhangqun Ye; Shaogang Wang
Journal:  Int Urol Nephrol       Date:  2018-03-19       Impact factor: 2.370

4.  Effectiveness and complications of mini-percutaneous nephrolithotomy in children: one center experience with 232 kidney units.

Authors:  Numan Baydilli; Halil Tosun; Emre Can Akınsal; Abdullah Gölbaşı; Sibel Yel; Deniz Demirci
Journal:  Turk J Urol       Date:  2019-11-14

5.  Enhanced super-mini-PCNL (eSMP): low renal pelvic pressure and high stone removal efficiency in a prospective randomized controlled trial.

Authors:  Wen Zhong; Junjun Wen; Linjie Peng; Guohua Zeng
Journal:  World J Urol       Date:  2020-05-26       Impact factor: 4.226

6.  Comparison of super-mini-PCNL and flexible ureteroscopy for the management of upper urinary tract calculus (1-2 cm) in children.

Authors:  Hongliang Jia; Jiuzhi Li; Bide Liu; Peixin Zhang; Ainiwaer Yusufu; Yukui Nan; Xun Li; Bin Wen; Chunlin Pu; Weili Du; Shuheng Wang
Journal:  World J Urol       Date:  2020-03-17       Impact factor: 4.226

7.  The Outcomes of Minimally Invasive Percutaneous Nephrolithotomy with Different Access Sizes for the Single Renal Stone ≤25 mm: A Randomized Prospective Study.

Authors:  Weimin Yu; Yuan Ruan; Zhuang Xiong; Yunlong Zhang; Ting Rao; Fan Cheng
Journal:  Urol Int       Date:  2021-07-01       Impact factor: 1.934

Review 8.  Minimally invasive surgery for pediatric renal and ureteric stones: A therapeutic update.

Authors:  Tao Peng; Hongcai Zhong; Baohui Hu; Shankun Zhao
Journal:  Front Pediatr       Date:  2022-08-18       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.